Cargando…
High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline
Stage IIB Hodgkin lymphoma (HL) patients, with a mediastinum-to-thorax (M/T) ratio of ≥0.33 or extranodal localization have a poor prognosis and are treated either as limited or advanced stage. We compared these two approaches in patients included in two randomized phase III trials enrolling previou...
Autores principales: | Rossi, Cédric, André, Marc, Dupuis, Jehan, Morschhauser, Franck, Joly, Bertrand, Lazarovici, Julien, Ghesquières, Hervé, Stamatoullas, Aspasia, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Gac, Anne-Claire, Moatti, Hannah, Fornecker, Luc-Matthieu, Deau, Bénédicte, Joubert, Clémentine, Fortpied, Catherine, Raemaekers, John, Federico, Massimo, Kanoun, Salim, Meignan, Michel, Traverse-Glehen, Alexandra, Cottereau, Anne-Ségolène, Casasnovas, René-Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713544/ https://www.ncbi.nlm.nih.gov/pubmed/35638548 http://dx.doi.org/10.3324/haematol.2021.280004 |
Ejemplares similares
-
Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells
por: Galtier, Jean, et al.
Publicado: (2022) -
PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion
por: Taylor, Joseph G., et al.
Publicado: (2022) -
Pathology review identifies frequent misdiagnoses in recurrent classic Hodgkin lymphoma in a nationwide cohort: implications for clinical and epidemiological studies
por: Boot, Max V., et al.
Publicado: (2022) -
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes
por: Wagner, Charlotte B., et al.
Publicado: (2023) -
Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
por: Ding, Kaiyang, et al.
Publicado: (2023)